Hyphens Pharma International Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 2/6

Hyphens Pharma International kazançlarla iyi bir şekilde karşılanan, 3.02% cari getiriye sahip, temettü ödeyen bir şirkettir.

Anahtar bilgiler

3.0%

Temettü verimi

0.1%

Geri Alım Getirisi

Toplam Hissedar Getirisi	3.1%
Gelecekteki Temettü Verimi	4.6%
Temettü Büyümesi	4.0%
Bir sonraki temettü ödeme tarihi	n/a
Eski temettü tarihi	n/a
Hisse başına temettü	S$0.0086
Ödeme oranı	25%

Son temettü ve geri alım güncellemeleri

Recent updates

Ödemelerde İstikrar ve Büyüme

Temettü verilerini getirme

İstikrarlı Temettü: 1J5 10 yıldan az bir süredir temettü ödüyor ve bu süre zarfında ödemeler dalgalı oldu.

Büyüyen Temettü: 1J5 şirketinin temettü ödemeleri artmış, ancak şirket yalnızca 6 yıldır temettü ödemiştir.

Piyasaya Karşı Temettü Getirisi

Hyphens Pharma International Piyasaya Karşı Temettü Getirisi

1J5 temettü verimi piyasa ile karşılaştırıldığında nasıldır?
Segment	Temettü Verimi
Şirket (1J5)	3.0%
Pazarın Alt %25'i (SG)	2.7%
Pazarın En İyi %25'i (SG)	6.0%
Sektör Ortalaması (Pharmaceuticals)	1.7%
Analist tahmini (1J5) (3 yıla kadar)	4.6%

Önemli Temettü: 1J5 'in temettüsü ( 3.02% ), SG piyasasındaki temettü ödeyenlerin en alttaki %25'inden ( 2.72% ) daha yüksektir.

Yüksek Temettü: 1J5 'in temettüsü ( 3.02% ), SG piyasasındaki temettü ödeyenlerin en üst %25'ine ( 5.98% ) kıyasla düşüktür.

Hissedarlara Ödenen Kazanç

Kazanç Kapsamı: Oldukça düşük ödeme oranı ( 25.5% ) ile 1J5 'un temettü ödemeleri kazançlarla oldukça iyi bir şekilde karşılanıyor.

Hissedarlara Nakit Ödeme

Nakit Akışı Kapsamı: Yüksek nakit ödeme oranı ( 497.4% ) nedeniyle, 1J5 'un temettü ödemeleri nakit akışları tarafından yeterince karşılanmıyor.

Hyphens Pharma International Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 2/6

Anahtar bilgiler

Son temettü ve geri alım güncellemeleri

Hyphens Pharma International Limited Approves a Final Tax Exempt (One-Tier) Dividend for the Financial Year Ended 31 December 2023

Hyphens Pharma International Limited Announces Special Interim Tax Exempt (One-Tier) Dividend for the Financial Year Ending 31 December 2023, Paid on 31 August 2023

Upcoming dividend of S$0.011 per share at 3.3% yield

Hyphens Pharma International Limited Approves Final Exempt (One-Tier) Dividend for the Year Ended 31 December 2021, Payable on 25 May 2022

Hyphens Pharma International Limited Recommends Final Tax Exempt (1-Tier) Dividend for the Financial Year Ended December 31, 2021

Hyphens Pharma International Limited Approves Final Exempt (One-Tier) Dividend for the Year Ended 31 December 2020, Payable on 25 May 2021

Recent updates

Hyphens Pharma International Limited Launches Ceradan Advanced Hand Balm, Specially Designed for Hand Eczema

Price target increased by 7.1% to S$0.38

First quarter 2024 earnings released

Hyphens Pharma International Limited Approves a Final Tax Exempt (One-Tier) Dividend for the Financial Year Ended 31 December 2023

Final dividend of S$0.0086 announced

Hyphens Pharma International Limited, Annual General Meeting, Apr 25, 2024

Consensus revenue estimates increase by 10%

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Insufficient new directors

Third quarter 2023 earnings released

Price target decreased by 10% to S$0.34

Hyphens Pharma International Limited Announces Special Interim Tax Exempt (One-Tier) Dividend for the Financial Year Ending 31 December 2023, Paid on 31 August 2023

Second quarter 2023 earnings released

Hyphens Pharma International Limited Appoints Zhang Yufan as Chief Financial Officer

Price target decreased by 8.9% to S$0.39

Now 23% undervalued after recent price drop

Upcoming dividend of S$0.011 per share at 3.3% yield

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Consensus EPS estimates increase by 14%

Full year 2022 earnings released: EPS: S$0.037 (vs S$0.023 in FY 2021)

Hyphens Pharma International Limited Launches its New Product, Meradan® Cream ("Meradan®") in Indonesia

Price target increased to S$0.41

Insufficient new directors

Price target increased to S$0.41

Consensus EPS estimates increase by 12%

Second quarter 2022 earnings released

Insufficient new directors

Hyphens Pharma International Limited Approves Final Exempt (One-Tier) Dividend for the Year Ended 31 December 2021, Payable on 25 May 2022

Price target decreased to S$0.35

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Hyphens Pharma International Limited, Annual General Meeting, Apr 27, 2022

Hyphens Pharma International Limited Recommends Final Tax Exempt (1-Tier) Dividend for the Financial Year Ended December 31, 2021

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target decreased to S$0.35

Third quarter 2021 earnings released: EPS S$0.004 (vs S$0.003 in 3Q 2020)

First quarter 2021 earnings released: EPS S$0.007 (vs S$0.007 in 1Q 2020)

Hyphens Pharma International Limited Approves Final Exempt (One-Tier) Dividend for the Year Ended 31 December 2020, Payable on 25 May 2021

Full year 2020 earnings released: EPS S$0.021 (vs S$0.022 in FY 2019)

Full year 2020 earnings released: EPS S$0.021 (vs S$0.022 in FY 2019)

Revenue and earnings miss expectations

Hyphens Pharma International Limited Appoints Exclusive Distributor in South Korea for Tdf Fairence T-Complex

New 90-day low: S$0.32

Price target lowered to S$0.38

New 90-day low: S$0.34

Hyphens Pharma International Limited Announces Board Changes

Analysts update estimates

First half earnings released

Ödemelerde İstikrar ve Büyüme

Piyasaya Karşı Temettü Getirisi

Hissedarlara Ödenen Kazanç

Hissedarlara Nakit Ödeme

Güçlü temettü ödeyen şirketleri keşfedin